INOVIO PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
INOVIO PHARMACEUTICALS, INC. (INO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$119.36 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2020-03-12
- INOVIO PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-12-31 was -$32.96M.
- INOVIO PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-09-30 was -$25.02M.
- INOVIO PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-06-30 was -$6.90M.
- INOVIO PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2018-03-31 was -$32.35M.
- INOVIO PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$119.36M.
- INOVIO PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$96.97M.
- INOVIO PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$89.01M.
- INOVIO PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$73.74M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$119.36M 10-K · filed 2020-03-12 | |||
| 2018-12-31 | -$32.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$57.98M derived: sum of 2 quarters · filed 2020-03-12 | -$64.88M derived: sum of 3 quarters · filed 2020-03-12 | -$96.97M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$25.02M 10-Q · filed 2018-11-08 | -$31.91M derived: sum of 2 quarters · filed 2018-11-08 | -$64.01M 10-Q · filed 2018-11-08 | -$86.35M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$6.90M 10-Q · filed 2018-08-07 | -$39.12M 10-Q · filed 2018-08-07 | -$61.34M derived: sum of 3 quarters · filed 2020-03-12 | -$95.89M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$32.35M 10-Q · filed 2018-05-09 | -$54.44M derived: sum of 2 quarters · filed 2020-03-12 | -$88.99M derived: sum of 3 quarters · filed 2020-03-12 | -$98.47M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$22.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$56.64M derived: sum of 2 quarters · filed 2020-03-12 | -$66.12M derived: sum of 3 quarters · filed 2020-03-12 | -$89.01M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$34.56M 10-Q · filed 2018-11-08 | -$44.04M derived: sum of 2 quarters · filed 2018-11-08 | -$66.93M 10-Q · filed 2018-11-08 | -$93.47M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | -$9.48M 10-Q · filed 2018-08-07 | -$32.57M 10-Q · filed 2018-08-07 | -$58.91M derived: sum of 3 quarters · filed 2019-03-12 | -$79.68M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | -$23.20M 10-Q · filed 2018-05-09 | -$49.44M derived: sum of 2 quarters · filed 2019-03-12 | -$70.20M derived: sum of 3 quarters · filed 2019-03-12 | -$88.90M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$26.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$47.00M derived: sum of 2 quarters · filed 2019-03-12 | -$65.70M derived: sum of 3 quarters · filed 2019-03-12 | -$73.74M 10-K · filed 2019-03-12 |
| 2016-09-30 | -$20.76M 10-Q · filed 2017-11-08 | -$39.47M derived: sum of 2 quarters · filed 2017-11-08 | -$47.51M 10-Q · filed 2017-11-08 | -$65.25M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | -$18.70M 10-Q · filed 2016-08-08 | -$26.75M 10-Q · filed 2016-08-08 | -$44.49M derived: sum of 3 quarters · filed 2018-03-14 | -$39.51M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | -$8.04M 10-Q · filed 2016-05-09 | -$25.79M derived: sum of 2 quarters · filed 2018-03-14 | -$20.81M derived: sum of 3 quarters · filed 2018-03-14 | -$27.08M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | -$17.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$12.77M derived: sum of 2 quarters · filed 2018-03-14 | -$19.04M derived: sum of 3 quarters · filed 2018-03-14 | -$29.91M 10-K · filed 2018-03-14 |
| 2015-09-30 | $4.98M 10-Q · filed 2016-11-09 | -$1.29M derived: sum of 2 quarters · filed 2016-11-09 | -$12.16M 10-Q · filed 2016-11-09 | -$19.76M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | -$6.27M 10-Q · filed 2016-08-08 | -$17.14M 10-Q · filed 2016-08-08 | -$24.74M derived: sum of 3 quarters · filed 2017-03-15 | -$32.19M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | -$10.87M 10-Q · filed 2016-05-09 | -$18.47M derived: sum of 2 quarters · filed 2017-03-15 | -$25.92M derived: sum of 3 quarters · filed 2017-03-15 | -$37.50M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | -$7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$15.04M derived: sum of 2 quarters · filed 2017-03-15 | -$26.63M derived: sum of 3 quarters · filed 2017-03-15 | -$38.30M 10-K · filed 2017-03-15 |
| 2014-09-30 | -$7.45M 10-Q · filed 2015-11-09 | -$19.03M derived: sum of 2 quarters · filed 2015-11-09 | -$30.71M 10-Q · filed 2015-11-09 | -$45.31M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | -$11.58M 10-Q · filed 2015-08-10 | -$22.15M 10-Q · filed 2015-08-10 | -$37.86M derived: sum of 3 quarters · filed 2016-03-14 | -$68.74M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | -$10.82M 10-Q · filed 2015-05-11 | -$26.28M derived: sum of 2 quarters · filed 2016-03-14 | -$57.15M derived: sum of 3 quarters · filed 2016-03-14 | -$68.01M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | -$15.45M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$46.33M derived: sum of 2 quarters · filed 2016-03-14 | -$57.18M derived: sum of 3 quarters · filed 2016-03-14 | -$66.03M 10-K · filed 2016-03-14 |
| 2013-09-30 | -$30.88M 10-Q · filed 2014-11-10 | -$41.73M derived: sum of 2 quarters · filed 2014-11-10 | -$50.57M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | -$10.85M 10-Q · filed 2014-08-11 | -$19.70M 10-Q · filed 2014-08-11 | ||
| 2012-12-31 | -$19.67M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |